Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 2
1977 1
1983 1
1986 1
1987 1
1988 1
1991 1
1992 3
1993 4
1996 2
1997 2
1998 4
2000 5
2002 1
2003 1
2005 9
2006 18
2007 12
2008 15
2009 14
2010 21
2011 25
2012 42
2013 62
2014 59
2015 50
2016 50
2017 51
2018 33
2019 35
2020 27
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

495 results
Results by year
Filters applied: . Clear all
Page 1
Biomarkers in multiple sclerosis.
Housley WJ, Pitt D, Hafler DA. Housley WJ, et al. Clin Immunol. 2015 Nov;161(1):51-8. doi: 10.1016/j.clim.2015.06.015. Epub 2015 Jul 2. Clin Immunol. 2015. PMID: 26143623 Review.
Substantial effort has been made over the last six decades to identify biomarkers for multiple sclerosis that can improve disease diagnosis, predict disease progression, and improve clinical outcomes. ...We start by discussing biomarkers currently in clinical use in …
Substantial effort has been made over the last six decades to identify biomarkers for multiple sclerosis that can improve dise …
Natalizumab in Multiple Sclerosis: Long-Term Management.
Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L. Clerico M, et al. Int J Mol Sci. 2017 Apr 29;18(5):940. doi: 10.3390/ijms18050940. Int J Mol Sci. 2017. PMID: 28468254 Free PMC article. Review.
Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Despite its effectiveness, there are growing concerns regarding the risk of progressive multifocal leukoencephalopathy (PML), a brain in …
Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patien …
Update on disease-modifying therapies for multiple sclerosis.
Vargas DL, Tyor WR. Vargas DL, et al. J Investig Med. 2017 Jun;65(5):883-891. doi: 10.1136/jim-2016-000339. Epub 2017 Jan 27. J Investig Med. 2017. PMID: 28130412 Review.
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system (CNS). ...However, the high risk of progressive multifocal leukoencephalopathy (PML), which is caused by JC virus infection in the brain, tempers the more wid
Multiple sclerosis (MS) is an autoimmune, demyelinating disease of the central nervous system (CNS). ...However, the high risk
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, Svenningsson A, Piehl F. Alping P, et al. Ann Neurol. 2016 Jun;79(6):950-8. doi: 10.1002/ana.24651. Epub 2016 Apr 20. Ann Neurol. 2016. PMID: 27038238 Clinical Trial.
OBJECTIVE: Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients who are stable on natalizumab switch to other therapies to avoid progressive multifocal leukoencephalopathy. METHODS: We compared outcomes for all RRMS pa …
OBJECTIVE: Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients who are stable …
Natalizumab treatment of multiple sclerosis: new insights.
Delbue S, Comar M, Ferrante P. Delbue S, et al. Immunotherapy. 2017 Jan;9(2):157-171. doi: 10.2217/imt-2016-0113. Epub 2016 Dec 22. Immunotherapy. 2017. PMID: 28004598 Review.
Natalizumab is a monoclonal antibody directed against the alpha4 chain of the very late activating antigen 4 and alpha4beta7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. It substantial …
Natalizumab is a monoclonal antibody directed against the alpha4 chain of the very late activating antigen 4 and alpha4beta7 integrins, pres …
Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.
Williamson EML, Berger JR. Williamson EML, et al. Neurotherapeutics. 2017 Oct;14(4):961-973. doi: 10.1007/s13311-017-0570-7. Neurotherapeutics. 2017. PMID: 28913726 Free PMC article. Review.
Progressive multifocal leukoencephalopathy (PML) is a rare, but serious, complication encountered in patients treated with a select number of disease-modifying therapies (DMTs) utilized in treating multiple sclerosis (MS). PML results from a viral infection in the b …
Progressive multifocal leukoencephalopathy (PML) is a rare, but serious, complication encountered in patients treated with a select number o …
Specific antibodies reacting to JC polyomavirus capsid protein mimotopes in sera from multiple sclerosis and other neurological diseases-affected patients.
Mazzoni E, Bononi I, Pietrobon S, Torreggiani E, Rossini M, Pugliatti M, Casetta I, Castellazzi M, Granieri E, Guerra G, Martini F, Tognon M. Mazzoni E, et al. J Cell Physiol. 2020 Jul;235(7-8):5847-5855. doi: 10.1002/jcp.29533. Epub 2020 Feb 3. J Cell Physiol. 2020. PMID: 32012272
JC (JC polyomavirus [JCPyV]), BK (BKPyV), and simian virus 40 (SV40) neurotropic polyomavirus footprints have been detected in brain tissue specimens and samples from patients affected by different neurological diseases. ...Our study indicates t
JC (JC polyomavirus [JCPyV]), BK (BKPyV), and simian virus 40 (SV40) neurotropic polyomavirus footprints
Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned.
Major EO, Yousry TA, Clifford DB. Major EO, et al. Lancet Neurol. 2018 May;17(5):467-480. doi: 10.1016/S1474-4422(18)30040-1. Lancet Neurol. 2018. PMID: 29656742 Review.
Detection of PML in systemically immunocompetent patients with multiple sclerosis treated with natalizumab points to a role for this drug in the pathophysiology of PML. ...Improved approaches to PML risk stratification are needed to guide treatment choices and surve …
Detection of PML in systemically immunocompetent patients with multiple sclerosis treated with natalizumab points to a role fo …
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.
Tan CS, Koralnik IJ. Tan CS, et al. Lancet Neurol. 2010 Apr;9(4):425-37. doi: 10.1016/S1474-4422(10)70040-5. Lancet Neurol. 2010. PMID: 20298966 Free PMC article. Review.
Additionally, the JC virus can also lead to novel neurological disorders such as JC virus granule cell neuronopathy and JC virus encephalopathy, and might also cause meningitis. The increasingly diverse populations at risk and the recent …
Additionally, the JC virus can also lead to novel neurological disorders such as JC virus granule cell neuronopa …
The biology of JC polyomavirus.
Assetta B, Atwood WJ. Assetta B, et al. Biol Chem. 2017 Jul 26;398(8):839-855. doi: 10.1515/hsz-2016-0345. Biol Chem. 2017. PMID: 28493815 Review.
JC polyomavirus (JCPyV) is the causative agent of a fatal central nervous system demyelinating disease known as progressive multifocal leukoencephalopathy (PML). PML occurs in people with underlying immunodeficiency or in individuals being treated with potent immuno
JC polyomavirus (JCPyV) is the causative agent of a fatal central nervous system demyelinating disease known as progressive mu
495 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback